Multiplex Laser vs. PDL (Pulsed Dye Laser ) in the Treatment of Surgical Scars
Status: | Completed |
---|---|
Conditions: | Cosmetic |
Therapuetic Areas: | Dermatology / Plastic Surgery |
Healthy: | No |
Age Range: | 18 - 90 |
Updated: | 8/23/2018 |
Start Date: | January 2015 |
End Date: | November 2017 |
Comparing the 595/1064nm Multiplex Laser to the 595nm PDL in the Treatment of Surgical Scars in a Blinded, Randomized, Controlled Trial
This study aims to determine if the 595nm Pulsed dye laser, the combined 595/1064nm Multiplex
laser or no treatment results in a better outcome in the quality of the surgical scar using
the multiplex cynergy laser, starting treatment the day of suture removal.
laser or no treatment results in a better outcome in the quality of the surgical scar using
the multiplex cynergy laser, starting treatment the day of suture removal.
This study aims to determine if the 595nm Pulsed dye laser, the combined 595/1064nm Multiplex
laser or no treatment results in a better outcome in the quality of the surgical scar using
the multiplex cynergy laser, starting treatment the day of suture removal.
Patients will be offered the opportunity of enrolling in the trial before their surgery. If
they qualify and agree to participate they will sign informed consent and Health Insurance
Portability and Accountability Act (HIPAA) form.
The surgical defect should be closed primarily, with the minimal scar length being 3cm. The
scar will be randomized into 3 equal thirds, each third will randomly receive either: no
treatment, 595nm PDL, or 595/1064nm Multiplex laser. A total of 3 laser treatments will be
performed over a period of 3 weeks (one treatment session performed every week), and the
patient will come in for a final follow up visit, for a final assessment of the scar using
the Patient and Observer Scar Assessment Scale (POSAS) system.
laser or no treatment results in a better outcome in the quality of the surgical scar using
the multiplex cynergy laser, starting treatment the day of suture removal.
Patients will be offered the opportunity of enrolling in the trial before their surgery. If
they qualify and agree to participate they will sign informed consent and Health Insurance
Portability and Accountability Act (HIPAA) form.
The surgical defect should be closed primarily, with the minimal scar length being 3cm. The
scar will be randomized into 3 equal thirds, each third will randomly receive either: no
treatment, 595nm PDL, or 595/1064nm Multiplex laser. A total of 3 laser treatments will be
performed over a period of 3 weeks (one treatment session performed every week), and the
patient will come in for a final follow up visit, for a final assessment of the scar using
the Patient and Observer Scar Assessment Scale (POSAS) system.
Inclusion Criteria:
- Fitzpatrick skin types 1-3
- Suture line should be at least 3 cm long
Exclusion Criteria:
- The patient should not be receiving any alternate systemic, topical or intralesional
treatment of the scars during the study
- Pregnant or lactating females
- Fitzpatrick skin type 4-6
- A history of keloids or hypertrophic scars
We found this trial at
1
site
1475 NW 12th Ave
Miami, Florida 33136
Miami, Florida 33136
(305) 243-1000
Principal Investigator: Keyvan Nouri, MD
Phone: 305-243-9443
University of Miami, Sylvester Comprehensive Cancer Center Sylvester Comprehensive Cancer Center integrates all cancer-related activities...
Click here to add this to my saved trials